Avaliação do efeito antidepressivo de Lepidium meyenii (Maca Peruana) em estudos pré-clínicos e clínicos: uma revisão integrativa da literatura
Nenhuma Miniatura disponível
Data
2023-03-17
Tipo de documento
Artigo Científico
Título da Revista
ISSN da Revista
Título de Volume
Área do conhecimento
Ciências da Saúde
Modalidade de acesso
Acesso aberto
Editora
Autores
Rodrigues, Sara
Brandão, Jullyanna
Orientador
Dalmagro, Ana Paula
Coorientador
Resumo
O transtorno depressivo maior (TDM) é uma das principais causas de incapacidade funcional e afeta cerca de 320 milhões de pessoas. Sua fisiopatologia pouco conhecida e tratamentos farmacológicos ineficientes impulsionam a busca de estratégias terapêuticas para essa desordem. Maca peruana (Lepidium meyenii) têm se mostrado um importante suplemento nutricional para aumentar libido e melhorar a sensação de bem-estar, mas seu potencial antidepressivo é pouco explorado. O objetivo da pesquisa é realizar uma revisão integrativa da literatura científica para avaliar o efeito antidepressivo de maca peruana (L. meyenii) em estudos
pré-clínicos e clínicos. Foi realizada uma busca de artigos nas bases de dados PubMed, LILACS e Biblioteca Virtual em Saúde (BVS) mediante os termos extraídos do DeCS: “Lepidium meyenii AND depression” e/ou “Lepidium meyenii AND depressive”. Foram revisados 16 artigos (1999-2022): 03 revisões de literatura, 08 artigos com experimentos pré-clínicos e 05 artigos sobre experimentos clínicos que se enquadraram na pergunta norteadora. As evidências pré-clínicas demonstram mais robustez quanto ao potencial antidepressivo de L. meyenii após exposição de animais a modelos de estresse crônico e cirúrgico, além da capacidade de modular níveis de neurotransmissores, corticosterona, neuroproteção e marcadores de estresse oxidativo.Quanto aos estudos clínicos, faltam ensaios que englobem um número significativo de sujeitos da pesquisa e maior tempo de observação comportamental dos participantes diante de situações estressoras. O tratamento com maca peruana parece exercer efeito antidepressivo, além de praticamente não desencadear toxicidade aguda e crônica; entretanto, são necessários estudos para implementar esse suplemento com segurança no tratamento do TDM.
Major depressive disorder (MDD) is one of the leading causes of functional disability, affecting more than 320 million people. Its poorly known pathophysiology and ineffective pharmacological treatments drive the search for therapeutic strategies for this disorder. Peruvian maca (Lepidium meyenii) is an important nutritional supplement to increase libido and improve patients’ well-being, but its antidepressant potential is poorly explored. The research aims to elaborate an integrative review of the scientific literature to assess the antidepressant effect of Peruvian maca (L. meyenii) in preclinical and clinical studies. A search for articles was carried out in the PubMed, LILACS, and Virtual Health Library (VHL) databases using the terms extracted from the DeCS: “Lepidium meyeniiAND depression” and/or “Lepidium meyeniiAND depressive”. Sixteen articles were reviewed (1999-2022): 03 literature reviews, 08 articles with preclinical experiments, and 05 articles regarding clinical experiments that fit the guiding question. Preclinical evidence demonstrates more robustness regarding the antidepressant potential of L. meyeniiafter exposing animals to chronic and surgical stress models, in addition to the capacity to modulate neurotransmitters, corticosterone, neuroprotection levels, and oxidative stress markers. As for clinical studies, there is a lack of trials encompassing many research subjects and more extended behavioral observation of participants in stressful situations. Treatment with Peruvian maca seems to have an antidepressant effect and practically does not trigger acute and chronic toxicity; however, more studies could be done to implement this supplement safelyin MDD treatment.
Major depressive disorder (MDD) is one of the leading causes of functional disability, affecting more than 320 million people. Its poorly known pathophysiology and ineffective pharmacological treatments drive the search for therapeutic strategies for this disorder. Peruvian maca (Lepidium meyenii) is an important nutritional supplement to increase libido and improve patients’ well-being, but its antidepressant potential is poorly explored. The research aims to elaborate an integrative review of the scientific literature to assess the antidepressant effect of Peruvian maca (L. meyenii) in preclinical and clinical studies. A search for articles was carried out in the PubMed, LILACS, and Virtual Health Library (VHL) databases using the terms extracted from the DeCS: “Lepidium meyeniiAND depression” and/or “Lepidium meyeniiAND depressive”. Sixteen articles were reviewed (1999-2022): 03 literature reviews, 08 articles with preclinical experiments, and 05 articles regarding clinical experiments that fit the guiding question. Preclinical evidence demonstrates more robustness regarding the antidepressant potential of L. meyeniiafter exposing animals to chronic and surgical stress models, in addition to the capacity to modulate neurotransmitters, corticosterone, neuroprotection levels, and oxidative stress markers. As for clinical studies, there is a lack of trials encompassing many research subjects and more extended behavioral observation of participants in stressful situations. Treatment with Peruvian maca seems to have an antidepressant effect and practically does not trigger acute and chronic toxicity; however, more studies could be done to implement this supplement safelyin MDD treatment.
Palavras-chave
Transtorno Depressivo Maior, Maca Peruana, Lepidium Meyenii